Men tend to experience more nausea and constipation when starting glucagon-like peptide-1 (GLP-1) receptor agonist medications like Ozempic and Wegovy, while women—particularly those with pregnancy history—show greater tolerance. This represents one of the few drug classes where sex-based differences in side effects have been clearly documented, according to obesity medicine specialists. Understanding these differences matters because it can help doctors tailor treatment plans and manage expectations for each patient. Why Do Men and Women React Differently to GLP-1 Drugs? GLP-1 medications work by mimicking a natural hormone released after eating, targeting receptors in the digestive system and brain to increase feelings of fullness and slow nutrient movement through the gut. This mechanism affects the entire body at a cellular level, but the way men and women experience these effects varies significantly. "This is one of the only drug classes that have been studied where that's the case," explains Dr. Jyotsna Ghosh, an obesity medicine physician at Johns Hopkins Medicine. "And that especially seems to be true in women who have had a pregnancy being less susceptible to side effects (especially nausea) with the medications." Men tend to have more nausea and constipation when getting started on these medications, she notes. The reasons behind these sex-based differences aren't fully understood, but the pattern is consistent enough that doctors now factor it into their prescribing decisions. Women with prior pregnancy experience appear to have developed some biological resilience to the gastrointestinal effects that trouble many men. What Are the Most Common Side Effects Men Should Expect? Beyond nausea and constipation, both men and women report other side effects when taking GLP-1 drugs. The most frequently observed is fatigue, which can significantly impact daily functioning. Another lesser-known but important side effect is anhedonia—a loss of pleasure in activities that normally bring joy. These two side effects can create a particularly challenging combination. "I've seen this too where people are fatigued and they're not getting the same endorphin rush that they used to get with the exercise," Dr. Ghosh explains. This one-two punch of reduced motivation and diminished reward can derail weight loss efforts if not actively managed with your healthcare provider. Muscle loss is another common concern with significant weight loss, though this isn't unique to GLP-1 medications. Between 10 and 20 percent of the weight people lose could be muscle, according to Dr. Wajahat Mehal, director of the Yale Weight Loss Program. The good news is that this can be substantially reduced through targeted interventions. How to Minimize Muscle Loss and Manage Side Effects - Strength Training: Incorporate weight training into your routine to preserve muscle mass during weight loss, which can significantly reduce the percentage of muscle lost over time. - Adequate Protein Intake: Eat enough protein daily to support muscle preservation, as this works synergistically with exercise to maintain lean body mass. - Track Symptoms Over Time: Monitor fatigue, nausea, constipation, and changes in mood or pleasure to identify patterns and report them to your doctor, who may adjust your dose or switch medications. - Communicate with Your Doctor: Report anhedonia and motivation changes early, as these can be addressed through medication adjustments before they derail your weight loss journey. Do GLP-1 Drugs Affect Sexual Function in Men? A common concern among male patients is whether GLP-1 medications might cause erectile dysfunction (ED), a worry stemming from older weight loss drugs like phentermine that did carry urinary side effects. The evidence for GLP-1s suggests the opposite effect. "If anything, it should help with blood flow, vascular distribution, and turning down inflammation, helping all the systems function better," Dr. Ghosh says. Dr. Mehal agrees, noting that GLP-1 drugs could actually improve erectile function, especially because ED is strongly associated with obesity, diabetes, and other metabolic conditions that these medications treat. Some initial data even shows increased availability of free testosterone and improved sperm quality, though the research remains mixed and more studies are needed. What's clear is that as the underlying metabolic conditions improve, sexual function typically improves alongside them. However, some people do report lower libido and reduced sexual desire—a side effect connected to anhedonia rather than physical dysfunction. This distinction matters because it suggests the issue is neurological rather than physiological, and may improve with dose adjustments or medication changes. Which GLP-1 Option Works Best for Different Needs? The GLP-1 landscape has expanded significantly since Ozempic (semaglutide) first arrived in 2017 for diabetes treatment. Today, patients have multiple options with different efficacy profiles and delivery methods. Semaglutide delivers approximately 15 percent weight loss on average, while tirzepatide—which works on two hormone receptors instead of one—delivers closer to 20 percent weight loss. On the horizon is retatrutide, a triple agonist that activates an additional hormone called glucagon, showing average weight loss of close to 25 percent in initial trials. The newer drugs also come with less severe and less prevalent digestive side effects. "Tirzepatide is predominantly an agonist for the GIP receptor, and that pathway induces less nausea," Dr. Mehal explains, referring to the gastric inhibitory polypeptide receptor. A pill form of Wegovy recently hit the market, offering an alternative to weekly injections. However, the oral version requires taking medication at the same time every day on an empty stomach and is slightly less effective, typically delivering 11 to 13 percent weight loss with a worse nausea profile than tirzepatide. The choice between pill and injection largely comes down to personal preference and lifestyle. What About Cost and Access? Cost remains a significant barrier for many patients, though the landscape is improving. As more options enter the market and competition increases, prices are likely to continue declining, particularly for patients without insurance coverage. Dr. Ghosh emphasizes the importance of affordable options: "Hopefully as there are more affordable options for people, they'll be able to choose things that are regulated, that they know exactly what they're getting, that their doctor is able to prescribe". Beyond weight loss alone, these medications treat multiple metabolic diseases including type 2 diabetes, sleep apnea, fatty liver disease, and coronary artery disease, making them valuable tools for comprehensive health improvement.
